A three-month licence extension is available for exocad users with either a Flex licence or a purchased upgrade contract for a perpetual licence. (Image: Andriy Popov/123RF.COM)

Corona Relief Program: Free licence extension for exocad users

By exocad
May 19, 2020

DARMSTADT, Germany: The worldwide spread of SARS-CoV-2 is presenting the dental industry with unprecedented economic and financial challenges. As an investment in its customers, the renowned Darmstadt-based software company exocad has announced its Corona Relief Program in order to support dental laboratories and dental practices.

Users who are experiencing financial challenges owing to the SARS-CoV-2 crisis and who meet certain conditions can apply for a three-month licence extension free of charge. Detailed conditions of participation are described on the exocad website. Interested users can take advantage of the free licence extension until 30 June 2020 by completing an online registration form provided on the website.

“With this campaign, we want to effectively support our international customers and make a contribution to the future of digital dentistry,” explained Tillmann Steinbrecher, exocad CEO. “It is particularly important for all of us to react quickly and flexibly in order to successfully overcome the effects of the coronavirus pandemic together. This is our small contribution to help our loyal community in these difficult times.”

Further information and registration for the exocad Corona Relief Program are available here.

  1. mercedes benavente says:

    me interesa recibir sus publicaciones

  2. Karla Fortuny says:

    Me interesa, pague suscripción y no se como voy a acceder a la información

  3. Rene Calvo says:

    Hola .requiero saber costo fechas de la especialidad en Rehabilitacion oral

  4. Roberto zurita robalino says:

    Inscripciones al congredo

  5. Paulo says:

    Tenho ainda em estoque cápsulas de Amálgama para uso, mas se tornou “fora de moda” aqui no Brasil restaurar dentes com esse material. Apesar de sua segurança, longevidade, os pacientes se recusam a ser tratados com essa alternativa. No início de minha carreira há 32 anos 60% das restaurações levavam o amálgama, hoje não chega a 0,5% . A “ditadura” da Estética e do risco de contaminação com o mercúrio baniu dos consultórios brasileiros essa opção barata e longeva. De vez em quando em consulta de rotina, ainda deparo com minhas restaurações de 30 ou mais anos em perfeitas condições. Não vejo tal desempenho com as Resinas Compostas, infelizmente estamos perdendo um grande aliado.

  6. Özden GÖk says:

    Hello!
    I am interested with UVC Tower.I’m from Turkey.Please would you send me details about
    how to reach and the price of this product.
    Thank you.

  7. George says:

    The last paragraph doesn’t make sense. Why should we expect the case fatality rate which is based on estimated number of cases as the denominator be expected to be higher than the infection fatality rate which is based on the ACTUAL number of cases??? The actual number of cases surely is likely to be lower and using the same numerator of actual deaths shouldn’t that mean a higher rate than the case fatality??? Again, showing that in actual sense this virus’ deadliness was largely overstated! You were so wrong, just come clean!

  8. Dr A K Bera says:

    To ban HCQ is a biased study,adverse effect for which it was banned is not found over several decades of its use in personal practice. Lancet has lost its credential by publication of such a baseless paper. With this new information, we’re really thankful.

  9. Dr A K Bera says:

    To ban HCQ is a biased study,adverse effect for which it was banned is not found over several decades of its use in personal practice. Lancet has lost its credential by publication of such a baseless paper.

  10. Dr Kunal Chatterjee says:

    We in the Indian Armed Forces have vast experience in the past of using Chloroquine and hydroxy chloroquine. Our soldiers have been placed in areas where malaria is endemic. And these drugs have been extensively used for prophylaxis and treatment. Prophylaxis was peculiar to military use and treatment was as per National guidelines. No major drug related reactions have been reported and it was the drug if choice. Hence the report of Lancet and response of WHO in stopping trials are baseless and over-the-top, without scientific basis.

© 2020 - All rights reserved - Dental Tribune International